Aptazyme capable of selective silencing of target miRNA by releasing an antisense sequence in hepatitis C virus-infected cells and use thereof
AssigneeIndustry-Academic Cooperation Foundation, Dankook University
InventorsSeong-Wook Lee, Chang-Ho Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to an aptazyme comprising an aptamer for hepatitis C virus (HCV) RNA-encoding component; a hammerhead ribozyme comprising an antisense sequence to microRNA at the site released by self-cleavage; and a communication module sequence that connects the aptamer and hammerhead ribozyme and triggers a self-cleavage activity of the hammerhead ribozyme upon binding of the aptamer with the HCV RNA-encoding component. The present aptazyme inhibits microRNA activity specifically in HCV proliferating cells and thus a composition of the present invention comprising the aptazyme can be effectively used for treatment of HCV-related diseases.
Claims4
An aptazyme capable of releasing an antisense sequence to microRNA specifically in HCV-infected cells, comprising:
- an aptamer for hepatitis C virus (HCV) RNA-encoding component;
- a hammerhead ribozyme comprising an antisense sequence to microRNA at the site released by self-cleavage;
- and
- a communication module sequence that connects the aptamer and hammerhead ribozyme and includes self-cleavage activity of hammerhead ribozyme upon binding of the aptamer with the HCV RNA-encoding component,
- wherein nucleic acid sequence of the aptazyme is represented by SEQ ID NO:
- 12 or 13.
Dependencies are inferred from the claim text.